Macrocyclic Chelators for Stable Actinium-225 Radioimmunoconjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chelators for alpha-emitting radionuclides like Actinium-225 face challenges in achieving high stability and specific activity in radioimmunoconjugates, often requiring harsh conditions or excessive amounts, and there is a need for site-specific methods to enhance safety and efficacy.
Innovation Solution
Development of macrocyclic chelators that can bind radiometals such as Actinium-225, allowing for stable radioimmunoconjugates with high specific activity and yield, using click chemistry for site-specific conjugation to targeting ligands like antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DOTA is used for actinium chelation, then chelation can be achieved, but high levels of DOTA per antibody are required and harsh conditions are needed
Solution Approach 1:
The patent modifies the DOTA chelator structure by introducing aromatic rings and heteroatoms to create novel macrocyclic chelators with enhanced actinium binding affinity. These structural parameter changes enable high-specific-activity actinium labeling without requiring excessive chelator amounts or harsh conditions
Solution Approach 2:
The patent creates composite structures by combining macrocyclic chelators with targeting ligands (antibodies, peptides, small molecules) to form radioimmunoconjugates. This composite approach integrates the metal-binding capability of the chelator with the target-specific recognition of the ligand, achieving both stable chelation and selective tumor targeting
2Productivity
If random conjugation methods are used, then radioimmunoconjugates can be produced, but site-specificity and safety are reduced
Solution Approach 1:
The patent incorporates the chelator into the targeting ligand structure beforehand, creating a pre-assembled conjugate that ensures the radionuclide will be delivered to the specific target site. This preliminary integration of the chelator-ligand complex eliminates random conjugation and guarantees site-specific delivery of the radiometal to tumor cells
Solution Approach 2:
The patent divides the radioimmunoconjugate into distinct functional segments: the targeting ligand portion that recognizes the tumor antigen and the chelator portion that binds the radionuclide. This segmentation allows each component to perform its specific function optimally while maintaining overall conjugate stability and target specificity
3Reliability
If high chelation ratios are used, then actinium binding can be achieved, but the complexity of the conjugate increases
Solution Approach 1:
The patent modifies the chelator's chemical parameters (ring size, heteroatom composition, substituent groups) to enhance actinium binding affinity and stability. These parameter optimizations allow effective chelation at lower chelator-to-actinium ratios, reducing the complexity of the final conjugate structure while maintaining high binding stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new chelators provide stable radioimmunoconjugates with improved safety and efficacy for targeted radiotherapy by ensuring high stability in vitro and in vivo, enabling selective delivery to tumor cells.
Implementation Method 1
macrocyclic chelators that can bind radiometals such as Actinium-225, allowing for stable radioimmunoconjugates
Data Source
AI summary
Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.